Development of new cancers in patients with DCIS: The M.D. Anderson experience

Annals of Surgical Oncology

Volumn 15, Issue 1, 2008, Pages 244-249

  Dawood, Shaheenah ^a,b   Broglio, Kristine ^a   Gonzalez Angulo, Ana M ^a   Kau, Shu Wan ^a   Yang, Wei ^a   Albarracin, Constance ^a   Meric, Funda ^a   Hortobagyi, Gabriel ^a   Theriault, Richard ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b DUBAI HOSPITAL   (United Arab Emirates)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER DIAGNOSIS; CANCER PATIENT; CARCINOGENESIS; DATA ANALYSIS; DATA BASE; DISEASE FREE SURVIVAL; DUCTAL CARCINOMA IN SITU; FEMALE; FOLLOW UP; HUMAN; INVASIVE CARCINOMA; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MAMMOGRAPHY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; SURVIVAL TIME; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, SECOND PRIMARY; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES;

EID: 38049141486     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-007-9661-8     Document Type: Article

References (18)

1. Schnitt SJ, Silen W, Sadowsky N, et al. Ductal carcinoma in situ (intraductal carcinoma of the breast). N Engl J Med 1988; 318:898-903
2. Miller FR, Soule HD, Tait L, et al. Xenograft model of progressive human proliferative breast disease. J Natl Cancer Inst 1993; 85:1725-1732
3. Ernster VL, Ballard-Barbash R, Barlow WE, et al. Detection of ductal carcinoma in situ in women undergoing screening mammography. J Natl Cancer Inst 2002; 94:1546-1554
4. Leonard GD, Swain SM. Ductal carcinoma in situ, complexities and challenges. J Natl Cancer Inst 2004; 96:906-920
5. Silverstein MJ, Barth A, Poller DN, et al. Ten-year results comparing mastectomy to excision and radiation therapy for ductal carcinoma in situ of the breast. Eur J Cancer 1995; 31:1425-1427
6. Fisher B, Land S, Mamounas E, et al. Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast Project experience. Semin Oncol 2001; 28:400-418
7. Bijker N, Meijnen P, Peterse JL, et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III Trial 10853-A study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol 2006; 24:3381-3387
8. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988; 16:1141-1154
9. R Development Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0, URL http://www.R-project.org (2006)
10. Bob Gray (2004). cmprsk: Subdistribution analysis of competing risks. R package version 2.1-5. http://www.r-project.org, http://www.biowww.dfci.harvard. edu/∼gray
11. Silverstein MJ, Lagios MD, Craig PH, et al. A prognostic index for ductal carcinoma in situ. Cancer 1996; 77:2267-2274
12. Webber VL, Heise H, Neifield JP, Costa J. Risk of subsequent breast carcinoma in a population of patients with in-situ breast carcinoma. Cancer 1981; 47:2928-2923
13. Claus EB, Stowe M, Carter D, Holford T. The risk of a contralateral breast cancer among women diagnosed with ductal and lobular carcinoma in situ: data from the Connecticut Tumor Registry. The Breast 2003; 12:451-456
14. Lehman CD, Gatsonis C, Kuhl CK, et al. ACRIN Trial 6667 Investigators Group. MRI evaluation of the contralateral breast in women with recently diagnosed breast cancer. N Engl J Med 2007; 356:1295-1303
15. Qaseem A, Snow V, Sherif K, et al. Clinical efficacy assessment subcommittee of the American College of Physicians. Screening mammography for women 40 to 49 years of age: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2007; 146:516-526
16. Bodai BI, Boyd B, Brown L, et al. Total cost comparison of 2 biopsy methods for nonpalpable breast lesions. Am J Manag Care 2001; 7:527-538
17. Secker-Walker RH, Vacek PM, Hooper GJ, Plante DA, Detsky AS. Screening for breast cancer: time, travel, and out-of-pocket expenses. J Natl Cancer Inst 1999; 91:702-708
18. Liberman L, Feng TL, Dershaw DD, Morris EA, Abramson AF. US-guided core breast biopsy: use and cost-effectiveness. Radiology 1998; 208:717-723